Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells (Q40432901)

20 September 2017

Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells (English)

1 reference

20 September 2017

1 reference

Eleanor J Cheadle

1

1 reference

20 September 2017

David E Gilham

2

1 reference

20 September 2017

Fiona C Thistlethwaite

3

1 reference

20 September 2017

John A Radford

4

1 reference

20 September 2017

Robert E Hawkins

5

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

British Journal of Haematology

20 September 2017

1 reference

20 September 2017

129

1 reference

20 September 2017

3

1 reference

20 September 2017

322-332

1 reference

Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.

20 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Adoptive transfer of anti-idiotypic T cells cure mice of disseminated B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Cancer and the chemokine network

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Phage libraries for generation of clinically useful antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Generating potent Th1/Tc1 T cell adoptive immunotherapy doses using human IL-12: Harnessing the immunomodulatory potential of IL-12 without the in vivo-associated toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

A novel 'sort-suicide' fusion gene vector for T cell manipulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Natural history of HLA expression during tumour development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Non-Hodgkin lymphoma: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Tumor rejection by disturbing tumor stroma cell interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Rapid detection of recombinant antibody fragments directed against cell-surface antigens by flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05456.X

10.1111/J.1365-2141.2005.05456.X

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference